Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis

A. Blauvelt, K. Reich, R. B. Warren, J. C. Szepietowski, B. Sigurgeirsson, S. K. Tyring, I. Messina, V. Bhosekar, J. Oliver, C. Papavassilis, J. Frueh, R. G.B. Langley*

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

16 Citations (Scopus)
Original languageEnglish
Pages (from-to)879-881
Number of pages3
JournalBritish Journal of Dermatology
Issue number3
Publication statusPublished - Sept 2017

Bibliographical note

Funding Information:
The authors received writing and editorial support from Andrew Horgan, PhD (BioScience Communications, New York, NY), which was supported by Novartis.

Cite this